Literature DB >> 8592549

Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

M den Heijer1, T Koster, H J Blom, G M Bos, E Briet, P H Reitsma, J P Vandenbroucke, F R Rosendaal.   

Abstract

BACKGROUND: Previous studies have suggested that hyperhomocysteinemia may be a risk factor for venous thrombosis. To assess the risk of venous thrombosis associated with hyperhomocysteinemia, we studied plasma homocysteine levels in patients with a first episode of deep-vein thrombosis and in normal control subjects.
METHODS: We measured plasma homocysteine levels in 269 patients with a first, objectively diagnosed episode of deep-vein thrombosis and in 269 healthy controls matched to the patients according to age and sex. Hyperhomocysteinemia was defined as a plasma homocysteine level above the 95th percentile in the control group (18.5 micromol per liter).
RESULTS: Of the 269 patients, 28 (10 percent) had plasma homocysteine levels above the 95th percentile for the controls, as compared with 13 of the controls (matched odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.2). The association between elevated homocysteine levels and venous thrombosis was stronger among women than among men and increased with age. The exclusion of subjects with other established risk factors for thrombosis (e.g., a deficiency of protein C, protein S, or antithrombin; resistance to activated protein C; pregnancy or recent childbirth; or oral-contraceptive use) did not materially affect the risk estimates.
CONCLUSIONS: High plasma homocysteine levels are a risk factor for deep-vein thrombosis in the general population.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8592549     DOI: 10.1056/NEJM199603213341203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  118 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Dilaveraki; I G Vlachonikolis; E Vardas; G Vrentzos; E Ganotakis; I A Mouzas; A Gravanis; D Emmanouel; E A Kouroumalis
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

Review 3.  [Angiology update].

Authors:  C Ranke; H J Trappe
Journal:  Med Klin (Munich)       Date:  1999-05-15

4.  Evaluation of Hypercoagulable States.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

5.  The Laboratory of Hypercoagulability: A Review of Present-Day Techniques.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

6.  Risk factors for thromboembolism: pathophysiology and detection.

Authors:  S Solymoss
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

Review 7.  Thrombophilia: a genetic predisposition to thrombosis.

Authors:  R A Sacher
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

8.  Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis.

Authors:  P A Isotalo; J G Donnelly
Journal:  Mol Diagn       Date:  2000-03

9.  Spectrum of MTHFR gene SNPs C677T and A1298C: a study among 23 population groups of India.

Authors:  Kallur Nava Saraswathy; Mohammad Asghar; Ratika Samtani; Benrithung Murry; Prakash Ranjan Mondal; Pradeep Kumar Ghosh; Mohinder Pal Sachdeva
Journal:  Mol Biol Rep       Date:  2011-12-07       Impact factor: 2.316

10.  A cross-sectional study to detect the prevalence of hyperhomocysteinemia in cases of deep vein thrombosis.

Authors:  Gautam V Kamat; S C Metgud; Vishwanath M Pattanshetti; A S Godhi
Journal:  Indian J Surg       Date:  2010-11-19       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.